463 related articles for article (PubMed ID: 26213109)
1. Pharmacological treatment of aldosterone excess.
Deinum J; Riksen NP; Lenders JW
Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
[TBL] [Abstract][Full Text] [Related]
2. Comparison of agents that affect aldosterone action.
Tamargo J; Solini A; Ruilope LM
Semin Nephrol; 2014 May; 34(3):285-306. PubMed ID: 25016400
[TBL] [Abstract][Full Text] [Related]
3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
4. Update in primary aldosteronism.
Stowasser M
J Clin Endocrinol Metab; 2009 Oct; 94(10):3623-30. PubMed ID: 19737921
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological treatment of primary aldosteronism.
Janmohamed S; Bouloux PM
Expert Opin Pharmacother; 2006 Apr; 7(5):563-73. PubMed ID: 16553572
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
Colussi G; Catena C; Sechi LA
J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone--a novel selective aldosterone blocker.
Zillich AJ; Carter BL
Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
12. What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?
Sica DA
Curr Cardiol Rep; 2011 Dec; 13(6):520-6. PubMed ID: 21993610
[TBL] [Abstract][Full Text] [Related]
13. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
Takeda Y
Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone antagonists in hypertension and heart failure.
Mantero F; Lucarelli G
Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone synthase inhibitors in cardiovascular and renal diseases.
Namsolleck P; Unger T
Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i62-i68. PubMed ID: 24493871
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
18. ARAs to the RESCUE.
Kaplan NM
J Am Soc Hypertens; 2016 Mar; 10(3):187-8. PubMed ID: 27408946
[No Abstract] [Full Text] [Related]
19. Eplerenone: a selective aldosterone receptor antagonist (SARA).
Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
[TBL] [Abstract][Full Text] [Related]
20. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]